Pacira BioSciences to Skip Q3 Results, Withdraw 2026 Guidance Amid Viatris Offer

Pacira BioSciences (PCRX) will not report Q3 2026 results or provide 2026 guidance while Viatris' $36.50 per share acquisition offer is pending. The merger would make Pacira a Viatris subsidiary. Pacira withdrew its 2026 financial guidance.

Original reporting

tradingview.com

Published Nov 5, 2026, 9:38 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Nov 6, 2026, 5:14 AM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

Pacira BioSciences to Skip Q3 Results, Withdraw 2026 Guidance Amid Viatris Offer — source image — Source · tradingview.com

Decision brief

The 30-second read

$PCRXBullishHigh

Why it matters

The tender offer triggers a premium to Pacira's recent share price, prompting immediate market reaction and likely price appreciation. The withdrawal of Q3 results and guidance underscores the transaction's priority and reduces short‑term earnings uncertainty.

Market read

The announcement is a material M&A event for a U.S.-listed biotech, creating a clear trading catalyst.

What to watch

Potential antitrust review and integration risk for Viatris may temper the premium.

Relevance 8/10Novelty 8/10Timing: immediate today

Background

Pacira BioSciences (PCRX) is a specialty pharmaceutical company focused on pain management. Viatris, a global generic and specialty medicines firm, has made a cash tender offer to acquire Pacira.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$PCRXBullishHigh confidence

Context

Pacira BioSciences announced it will skip Q3 results and withdrew guidance as Viatris' $36.50 per share cash tender offer is pending.

Expected impact

likely upside as market prices in the acquisition premium

Evidence & confidence

The cash offer at $36.50 represents a clear premium to recent trading levels, prompting buyers to bid up the stock.

Market effects

Sector

Potential consolidation in the pain management/medical device sector as Viatris expands its portfolio.

Regional

Limited to U.S. biotech market; no broader regional effect.

Global

Modest, primarily affects investors tracking M&A activity in healthcare.

Counterpoint

What could challenge this read

Deal could face regulatory or financing hurdles, risking a pull‑back in Pacira price.

Key entities

Company
Pacira BioSciences
Target of the acquisition, ticker PCRX.
Company
Viatris
Acquirer offering $36.50 per share in cash.

Read at source ← All news

$VTRSHighAI 8/10

Vitaris' Q3 Loss Expands To $325 Mln Despite Consistent Sales; 2026 Guidance Raised

Vitaris Inc. (VTRS) reported a wider Q3 net loss of $325.3M, up from $128.2M last year, due to higher tax provisions and litigation costs. Revenue was stable at $3.74B. EBITDA rose to $937.5M. The company raised 2026 guidance, expecting revenue of $14.55B-$14.95B and adjusted EBITDA of $4.30B-$4.50B. Shares fell 1.30% to $18.97.

rttnews.comNov 6

$VTRSHigh

Jefferies raises Viatris stock price target to $22 on guidance lift

Jefferies raised its price target for Viatris (VTRS) to $22 from $20, citing raised guidance despite a Q3 revenue miss. The stock is up 94% over the past year. Viatris reported adjusted EPS of $0.71, beating estimates, and raised full-year guidance for revenue, EBITDA, and EPS growth. China performance is slowing, but the estrogen patch is a growth driver. Supply shortages in Europe and emerging markets are expected to impact Q4 results.

investing.comNov 6

$PCRXHighAI 8/10

Pacira Halts 2026 Guidance as Viatris $36.50 Tender Offer Begins

Pacira BioSciences (PCRX) announced that Viatris has begun a tender offer for all its shares at $36.50 per share. Pacira has suspended its Q3 2026 earnings report and withdrawn its 2026 guidance. The deal is subject to regulatory approvals and other conditions, with no guarantee of completion.

minichart.com.sgNov 6

$VTRSMedAI 8/10

Viatris Inc (VTRS) (Q3 2026) Earnings Call Highlights: Raised Guidance, Pacira Deal

Viatris (VTRS) reported Q3 2026 earnings, raising guidance despite supply constraints at its Nashik facility, which reduced revenues by $100M. The company faces challenges in Europe, China, and product exclusivity losses. CEO Scott Smith hinted at potential $5B EBITDA by 2027, earlier than previously expected. Growth opportunities include EXPAREL, HRT patches, and selatogrel. The company remains optimistic about its 2027 outlook and long-term growth drivers.

finance.yahoo.comNov 5

$VTRSMed

Viatris Inc. Q3 2026 Earnings Call Summary

Viatris Inc. reported Q3 2026 earnings, highlighting growth in North America and Greater China, driven by cardiovascular products and e-commerce. Supply constraints in Europe and emerging markets resulted in a $100 million revenue loss. The company plans to acquire Pacira BioSciences for $1 billion in revenue by 2027. FDA reviews and pipeline milestones are expected in 2027. Management raised 2026 guidance but withheld 2027 specifics. Growth in China moderated due to procurement policy changes.